Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03766035 · ClinicalTrials.gov registry record
Cholangioscopy in Primary Sclerosing Cholangitis (PSC)
A clinical trial, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 43
- Enrollment target
NCT03766035: Completed study, sponsored by Boston Scientific Corporation.
NCT03766035 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03766035 has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
Study Summary
To demonstrate the clinical utility of the addition of per oral cholangioscopy (POCS) to standard endoscopic retrograde cholangiopancreatography (ERCP) with brushing cytology for diagnosis and early detection of cholangiocarcinoma in patients diagnosed with primary sclerosing cholangitis (PSC).
Primary Outcome
Diagnostic accuracy of POCS visualization for cholangiocarcinoma evaluated clinically at 12 months after initial POCS procedure by clinical presentation.
Interventions
- DEVICE SpyGlass DS I - II
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-12-06 |
| Est. Completion | 2022-12-12 |
What the finished NCT03766035 record still lists
NCT03766035 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 43 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which SpyGlass DS I - II is the first listed.
NCT03766035 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03766035 about?
NCT03766035 is a clinical study titled "Cholangioscopy in Primary Sclerosing Cholangitis (PSC)". To demonstrate the clinical utility of the addition of per oral cholangioscopy (POCS) to standard endoscopic retrograde cholangiopancreatography (ERCP) with brushing cytology for diagnosis and early detection of cholangiocarcinoma in patients diagnosed with primary sclerosing cholangitis (PSC).
What is the current status of trial NCT03766035?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2018-12-06. Estimated completion is 2022-12-12.
What interventions are being tested in trial NCT03766035?
The interventions under investigation include: SpyGlass DS I - II (DEVICE).
Who is sponsoring clinical trial NCT03766035?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI